



Clinical trial results:

An Integrated Pharmacokinetic and Safety Open-label Basket Trial of Daprodustat for the Treatment of Anemia Associated with Chronic Kidney Disease in Male and Female Children and Adolescents Aged 3 Months to Under 18 Years Requiring or Not Requiring Dialysis

Summary

EudraCT number	2021-002013-34
Trial protocol	ES IT FR AT BE PL Outside EU/EEA
Global end of trial date	17 March 2025

Results information

Result version number	v1 (current)
This version publication date	23 October 2025
First version publication date	23 October 2025

Trial information

Trial identification

Sponsor protocol code	214066
-----------------------	--------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT05682326
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	GlaxoSmithKline
Sponsor organisation address	79 New Oxford Street, London, United Kingdom, WC1A 1DG
Public contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com
Scientific contact	GSK Response Center, GlaxoSmithKline, 1 8664357343, GSKClinicalSupportHD@gsk.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	Yes
EMA paediatric investigation plan number(s)	EMA-001452-PIP01-13
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	17 March 2025
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	17 March 2025
Was the trial ended prematurely?	Yes

Notes:

General information about the trial

Main objective of the trial:

Describe the safety of daprodustat, overall (all ages) and in each age group.

Protection of trial subjects:

NA

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	06 September 2023
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Japan: 3
Country: Number of subjects enrolled	Korea, Republic of: 1
Worldwide total number of subjects	4
EEA total number of subjects	0

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	4
Adults (18-64 years)	0
From 65 to 84 years	0
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Participants enrolled in 2 sub-trials under master protocol. The non-dialysis (ND) sub-trial enrolled pediatric participants with anemia associated with chronic kidney disease (CKD) not yet requiring dialysis and the dialysis (D) sub-trial enrolled pediatric participants with anemia associated with CKD requiring dialysis, both in non-US countries.

Pre-assignment

Screening details:

A total of 4 participants were enrolled. As pre-specified in protocol design, data for the 2 sub-trials (ND and D) have been presented in two arms for this study.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Participants requiring Dialysis (D)

Arm description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Arm type	Experimental
Investigational medicinal product name	Daprodustat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral daprodustat (1 to 24 mg QD equivalent) for 52 weeks, dose adjusted per Baseline Hgb and clinical status.

Arm title	Participants not yet requiring Dialysis (ND)
------------------	--

Arm description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the non-dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Arm type	Experimental
Investigational medicinal product name	Daprodustat
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Oral daprodustat (1 to 24 mg QD equivalent) for 52 weeks, dose adjusted per baseline Hgb and clinical status.

Number of subjects in period 1	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)
Started	2	2
Completed	1	2
Not completed	1	0
Consent withdrawn by subject	1	-

Baseline characteristics

Reporting groups

Reporting group title	Participants requiring Dialysis (D)
-----------------------	-------------------------------------

Reporting group description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Reporting group title	Participants not yet requiring Dialysis (ND)
-----------------------	--

Reporting group description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the non-dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Reporting group values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)	Total
Number of subjects	2	2	4
Age Categorical			
Units: Participants			
12 to <18 years	2	2	4
Sex: Female, Male			
Units: Participants			
Female	2	0	2
Male	0	2	2
Race/Ethnicity, Customized			
"All Other Races" category (Asian - East Asian Heritage and Asian - Japanese Heritage where 0<n<11) are combined into one category to maintain participant confidentiality and privacy.			
Units: Subjects			
All Other Races	2	2	4

End points

End points reporting groups

Reporting group title	Participants requiring Dialysis (D)
Reporting group description: Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).	
Reporting group title	Participants not yet requiring Dialysis (ND)
Reporting group description: Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the non-dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).	

Primary: Number of participants with any adverse events (AEs) and serious adverse events (SAEs)

End point title	Number of participants with any adverse events (AEs) and serious adverse events (SAEs) ^[1]
End point description: An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. SAEs are defined as any untoward medical occurrence that, at any dose: results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other situations as per medical and scientific judgement of the Investigator. The analysis was performed on the Safety Set that included all participants who were enrolled and took at least one dose of study medication.	
End point type	Primary
End point timeframe: Up to 56 weeks	
Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: There are no statistical data to report.	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[2]	2 ^[3]		
Units: Participants				
Any AEs	2	2		
Any SAEs	1	0		

Notes:
[2] - Safety Set
[3] - Safety Set

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with adverse event of special interests (AESIs)

End point title	Number of participants with adverse event of special interests (AESIs) ^[4]
-----------------	---

End point description:

AESIs are AEs of scientific interest specific to the drug class as per investigator assessment. AESI included: Death, Myocardial Infarction (MI), stroke, Heart Failure (HF), thromboembolic events, thrombosis of vascular access, Thrombosis and/or tissue ischemia secondary to excessive erythropoiesis, New diagnosis of hypertension or worsening of existing hypertension, Cancer related mortality and tumor progression and recurrence, Esophageal and gastric erosions. Number of participants with any AESIs have been presented. Safety Set.

End point type	Primary
----------------	---------

End point timeframe:

Up to 56 weeks

Notes:

[4] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[5]	2 ^[6]		
Units: Participants	0	0		

Notes:

[5] - Safety Set

[6] - Safety Set

Statistical analyses

No statistical analyses for this end point

Primary: Number of participants with AEs leading to study intervention discontinuation

End point title	Number of participants with AEs leading to study intervention discontinuation ^[7]
-----------------	--

End point description:

All AEs leading to study intervention discontinuation were collected. Number of participants with any AEs leading to study intervention discontinuation have been presented. Safety Set.

End point type	Primary
----------------	---------

End point timeframe:

Up to 52 weeks

Notes:

[7] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: There are no statistical data to report.

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[8]	2 ^[9]		
Units: Participants	0	0		

Notes:

[8] - Safety Set

[9] - Safety Set

Statistical analyses

Secondary: Change from Baseline in hematology parameter: Hematocrit

End point title	Change from Baseline in hematology parameter: Hematocrit
-----------------	--

End point description:

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[10]	2 ^[11]		
Units: Percentage of red blood cells in blood				
arithmetic mean (standard deviation)				
Week 4, n=1,2	0.0160 (± 99999)	0.0030 (± 0.03818)		
Week 8, n=1,2	0.0530 (± 99999)	0.0025 (± 0.03889)		
Week 12, n=1,2	-0.0280 (± 99999)	0.0135 (± 0.01485)		
Week 16, n=1,2	-0.0200 (± 99999)	-0.0185 (± 0.03889)		
Week 20, n=1,2	0.0000 (± 99999)	-0.0005 (± 0.01909)		
Week 24, n=1,2	0.0050 (± 99999)	0.0060 (± 0.02687)		
Week 28, n=1,2	0.0340 (± 99999)	-0.0050 (± 0.03536)		
Week 32, n=1,1	0.0350 (± 99999)	0.0370 (± 99999)		
Week 36, n=1,2	0.0070 (± 99999)	0.0095 (± 0.02333)		
Week 40, n=1,2	-0.0220 (± 99999)	0.0270 (± 0.04667)		
Week 44, n=1,2	-0.0020 (± 99999)	-0.0060 (± 0.03677)		
Week 48, n=0,2	-88888 (± 88888)	0.0035 (± 0.01909)		
Week 52, n=1,2	-0.0320 (± 99999)	0.0020 (± 0.01980)		

Notes:

[10] - Safety Set

[11] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hematology parameter: Reticulocytes/Erythrocytes

End point title	Change from Baseline in hematology parameter: Reticulocytes/Erythrocytes
End point description:	
Blood samples were collected to analyze the hematology parameter: Reticulocytes/Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[12]	2 ^[13]		
Units: Ratio of Reticulocytes to Erythrocytes				
arithmetic mean (standard deviation)				
Week 4, n=1,2	0.0080 (± 99999)	-0.0039 (± 0.00686)		
Week 8, n=1,2	-0.0020 (± 99999)	0.0031 (± 0.00134)		
Week 12, n=1,2	0.0060 (± 99999)	-0.0012 (± 0.00594)		
Week 16, n=1,2	0.0100 (± 99999)	-0.0024 (± 0.00481)		
Week 20, n=1,2	0.0110 (± 99999)	0.0001 (± 0.00693)		
Week 24, n=1,2	0.0060 (± 99999)	-0.0020 (± 0.00700)		
Week 28, n=1,2	0.0040 (± 99999)	0.0007 (± 0.00467)		
Week 32, n=1,1	0.0030 (± 99999)	-0.0037 (± 99999)		
Week 36, n=1,2	0.0020 (± 99999)	0.0010 (± 0.00573)		
Week 40, n=1,2	0.0070 (± 99999)	-0.0020 (± 0.00849)		
Week 44, n=1,2	0.0100 (± 99999)	0.0010 (± 0.00714)		
Week 48, n=0,2	-88888 (± 88888)	0.0026 (± 0.00771)		
Week 52, n=1,2	0.0040 (± 99999)	0.0018 (± 0.00453)		

Notes:

[12] - Safety Set

[13] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hematology parameter: Erythrocytes

End point title	Change from Baseline in hematology parameter: Erythrocytes
-----------------	--

End point description:

Blood samples were collected to analyze the hematology parameter: Erythrocytes. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[14]	2 ^[15]		
Units: Trillion cells per Liter (10 ¹² cells/L)				
arithmetic mean (standard deviation)				
Week 4, n=1,2	0.130 (± 99999)	0.060 (± 0.4243)		
Week 8, n=1,2	0.480 (± 99999)	0.045 (± 0.4313)		
Week 12, n=1,2	-0.350 (± 99999)	0.060 (± 0.2546)		
Week 16, n=1,2	-0.350 (± 99999)	-0.280 (± 0.5374)		
Week 20, n=1,2	0.010 (± 99999)	-0.050 (± 0.2970)		
Week 24, n=1,2	0.030 (± 99999)	0.025 (± 0.3889)		
Week 28, n=1,2	0.250 (± 99999)	-0.095 (± 0.4879)		
Week 32, n=1,1	0.350 (± 99999)	0.350 (± 99999)		
Week 36, n=1,2	0.030 (± 99999)	0.050 (± 0.3111)		
Week 40, n=1,2	-0.330 (± 99999)	0.310 (± 0.4808)		
Week 44, n=1,2	-0.260 (± 99999)	-0.080 (± 0.5515)		

Week 48, n=0,2	-88888 (± 88888)	-0.025 (± 0.2758)		
Week 52, n=1,2	-0.490 (± 99999)	-0.050 (± 0.2687)		

Notes:

[14] - Safety Set

[15] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count

End point title	Change from Baseline in hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count
-----------------	---

End point description:

Blood samples were collected to analyze the hematology parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Leukocytes and Platelet count. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[16]	2 ^[17]		
Units: Giga cells per Liter (10 ⁹ cells/L)				
arithmetic mean (standard deviation)				
Basophils: Week 4, n=1,2	0.0120 (± 99999)	0.0007 (± 0.01509)		
Basophils: Week 8, n=1,2	-0.0177 (± 99999)	0.0087 (± 0.01232)		
Basophils: Week 12, n=1,2	-0.0011 (± 99999)	0.0093 (± 0.01312)		
Basophils: Week 16, n=1,2	-0.0062 (± 99999)	-0.0038 (± 0.02292)		
Basophils: Week 20, n=1,2	0.0085 (± 99999)	0.0162 (± 0.02295)		
Basophils: Week 24, n=1,2	-0.0044 (± 99999)	0.0066 (± 0.02353)		
Basophils: Week 28, n=1,2	0.0182 (± 99999)	0.0003 (± 0.01458)		
Basophils: Week 32, n=1,1	-0.0209 (± 99999)	0.0314 (± 99999)		
Basophils: Week 36, n=1,2	-0.0091 (± 99999)	0.0051 (± 0.02139)		

Basophils: Week 40, n=1,2	-0.0020 ($\pm$ 99999)	0.0063 ($\pm$ 0.00522)		
Basophils: Week 44, n=1,2	-0.0091 ($\pm$ 99999)	0.0001 ($\pm$ 0.00017)		
Basophils: Week 48, n=0,2	-88888 ($\pm$ 88888)	0.0059 ($\pm$ 0.00833)		
Basophils: Week 52, n=1,2	0.0012 ($\pm$ 99999)	-0.0001 ($\pm$ 0.00008)		
Eosinophils: Week 4, n=1,2	0.0146 ($\pm$ 99999)	0.4193 ($\pm$ 0.63542)		
Eosinophils: Week 8, n=1,2	-0.0962 ($\pm$ 99999)	0.2385 ($\pm$ 0.30899)		
Eosinophils: Week 12, n=1,2	-0.0072 ($\pm$ 99999)	0.2547 ($\pm$ 0.11973)		
Eosinophils: Week 16, n=1,2	0.0239 ($\pm$ 99999)	0.1184 ($\pm$ 0.15326)		
Eosinophils: Week 20, n=1,2	-0.0037 ($\pm$ 99999)	0.0989 ($\pm$ 0.13988)		
Eosinophils: Week 24, n=1,2	0.0203 ($\pm$ 99999)	0.0698 ($\pm$ 0.18356)		
Eosinophils: Week 28, n=1,2	-0.0578 ($\pm$ 99999)	0.0238 ($\pm$ 0.07607)		
Eosinophils: Week 32, n=1,1	-0.1571 ($\pm$ 99999)	0.2913 ($\pm$ 99999)		
Eosinophils: Week 36, n=1,2	-0.0775 ($\pm$ 99999)	0.0395 ($\pm$ 0.14069)		
Eosinophils: Week 40, n=1,2	-0.1208 ($\pm$ 99999)	0.0357 ($\pm$ 0.07683)		
Eosinophils: Week 44, n=1,2	-0.0522 ($\pm$ 99999)	0.0395 ($\pm$ 0.02754)		
Eosinophils: Week 48, n=0,2	-88888 ($\pm$ 88888)	0.1645 ($\pm$ 0.10537)		
Eosinophils: Week 52, n=1,2	-0.0628 ($\pm$ 99999)	0.0390 ($\pm$ 0.00136)		
Lymphocytes: Week 4, n=1,2	0.2799 ($\pm$ 99999)	-0.2606 ($\pm$ 0.01499)		
Lymphocytes: Week 8, n=1,2	0.4370 ($\pm$ 99999)	-0.4114 ($\pm$ 0.49299)		
Lymphocytes: Week 12, n=1,2	-0.2165 ($\pm$ 99999)	-0.2552 ($\pm$ 0.57253)		
Lymphocytes: Week 16, n=1,2	-0.2907 ($\pm$ 99999)	-0.2009 ($\pm$ 0.40885)		
Lymphocytes: Week 20, n=1,2	0.1325 ($\pm$ 99999)	-0.3649 ($\pm$ 0.58710)		
Lymphocytes: Week 24, n=1,2	-0.1535 ($\pm$ 99999)	-0.3050 ($\pm$ 0.58684)		
Lymphocytes: Week 28, n=1,2	0.0289 ($\pm$ 99999)	-0.2517 ($\pm$ 0.50673)		
Lymphocytes: Week 32, n=1,1	-1.1501 ($\pm$ 99999)	0.6357 ($\pm$ 99999)		
Lymphocytes: Week 36, n=1,2	0.0581 ($\pm$ 99999)	-0.4619 ($\pm$ 1.00143)		
Lymphocytes: Week 40, n=1,2	-0.2134 ($\pm$ 99999)	-0.4961 ($\pm$ 0.05108)		
Lymphocytes: Week 44, n=1,2	0.5638 ($\pm$ 99999)	-0.4021 ($\pm$ 0.50620)		
Lymphocytes: Week 48, n=0,2	-88888 ($\pm$ 88888)	-0.1701 ($\pm$ 0.33923)		
Lymphocytes: Week 52, n=1,2	0.4700 ($\pm$ 99999)	-0.5256 ($\pm$ 0.60026)		
Monocytes: Week 4, n=1,2	0.0408 ($\pm$ 99999)	-0.0318 ($\pm$ 0.03079)		

Monocytes: Week 8, n=1,2	0.1094 (± 99999)	0.0230 (± 0.15981)		
Monocytes: Week 12, n=1,2	-0.0258 (± 99999)	0.0536 (± 0.01924)		
Monocytes: Week 16, n=1,2	-0.0289 (± 99999)	0.0148 (± 0.00684)		
Monocytes: Week 20, n=1,2	0.0132 (± 99999)	-0.0307 (± 0.11217)		
Monocytes: Week 24, n=1,2	-0.0404 (± 99999)	-0.0310 (± 0.04098)		
Monocytes: Week 28, n=1,2	0.0169 (± 99999)	-0.0314 (± 0.06868)		
Monocytes: Week 32, n=1,1	-0.2902 (± 99999)	0.0410 (± 99999)		
Monocytes: Week 36, n=1,2	-0.0410 (± 99999)	-0.0596 (± 0.01360)		
Monocytes: Week 40, n=1,2	-0.0708 (± 99999)	0.0884 (± 0.20985)		
Monocytes: Week 44, n=1,2	0.0601 (± 99999)	-0.0110 (± 0.02690)		
Monocytes: Week 48, n=0,2	-88888 (± 88888)	0.0492 (± 0.04132)		
Monocytes: Week 52, n=1,2	0.0164 (± 99999)	-0.0112 (± 0.01583)		
Neutrophils: Week 4, n=1,2	-0.1973 (± 99999)	-0.1626 (± 0.16602)		
Neutrophils: Week 8, n=1,2	-3.5926 (± 99999)	0.4712 (± 1.43005)		
Neutrophils: Week 12, n=1,2	-0.1094 (± 99999)	0.4876 (± 0.20136)		
Neutrophils: Week 16, n=1,2	-1.7681 (± 99999)	1.3315 (± 1.27070)		
Neutrophils: Week 20, n=1,2	-0.8705 (± 99999)	-0.0296 (± 0.38241)		
Neutrophils: Week 24, n=1,2	-1.2919 (± 99999)	0.2346 (± 0.30353)		
Neutrophils: Week 28, n=1,2	1.6839 (± 99999)	-0.1160 (± 0.33096)		
Neutrophils: Week 32, n=1,1	-5.3517 (± 99999)	1.1306 (± 99999)		
Neutrophils: Week 36, n=1,2	1.2095 (± 99999)	0.4269 (± 0.70272)		
Neutrophils: Week 40, n=1,2	-0.2730 (± 99999)	1.0158 (± 0.85667)		
Neutrophils: Week 44, n=1,2	0.5974 (± 99999)	0.0185 (± 0.11095)		
Neutrophils: Week 48, n=0,2	-88888 (± 88888)	0.3055 (± 0.11948)		
Neutrophils: Week 52, n=1,2	-0.0248 (± 99999)	0.6728 (± 0.91533)		
Leukocytes: Week 4, n=1,2	0.150 (± 99999)	-0.045 (± 0.7849)		
Leukocytes: Week 8, n=1,2	-3.160 (± 99999)	0.315 (± 2.4254)		
Leukocytes: Week 12, n=1,2	-0.360 (± 99999)	0.510 (± 0.5798)		
Leukocytes: Week 16, n=1,2	-2.070 (± 99999)	1.240 (± 0.6505)		
Leukocytes: Week 20, n=1,2	-0.720 (± 99999)	-0.315 (± 1.2516)		
Leukocytes: Week 24, n=1,2	-1.470 (± 99999)	-0.060 (± 1.1879)		

Leukocytes: Week 28, n=1,2	1.690 (± 99999)	-0.385 (± 1.0112)		
Leukocytes: Week 32, n=1,1	-6.970 (± 99999)	2.130 (± 99999)		
Leukocytes: Week 36, n=1,2	1.140 (± 99999)	-0.070 (± 1.8809)		
Leukocytes: Week 40, n=1,2	-0.680 (± 99999)	0.605 (± 0.9970)		
Leukocytes: Week 44, n=1,2	1.160 (± 99999)	-0.390 (± 0.7212)		
Leukocytes: Week 48, n=0,2	-88888 (± 88888)	0.310 (± 0.4384)		
Leukocytes: Week 52, n=1,2	0.400 (± 99999)	0.170 (± 0.3253)		
Platelet count: Week 4, n=1,2	16.0 (± 99999)	-30.0 (± 26.87)		
Platelet count: Week 8, n=1,2	-31.0 (± 99999)	-41.5 (± 34.65)		
Platelet count: Week 12, n=1,2	-11.0 (± 99999)	-32.0 (± 39.60)		
Platelet count: Week 16, n=1,2	-5.0 (± 99999)	-47.0 (± 14.14)		
Platelet count: Week 20, n=1,2	5.0 (± 99999)	-39.5 (± 27.58)		
Platelet count: Week 24, n=1,2	-11.0 (± 99999)	-10.0 (± 7.07)		
Platelet count: Week 28, n=1,2	10.0 (± 99999)	-14.5 (± 6.36)		
Platelet count: Week 32, n=1,1	6.0 (± 99999)	1.0 (± 99999)		
Platelet count: Week 36, n=1,2	-4.0 (± 99999)	-25.0 (± 0.00)		
Platelet count: Week 40, n=1,2	23.0 (± 99999)	-18.5 (± 27.58)		
Platelet count: Week 44, n=1,2	28.0 (± 99999)	-7.5 (± 37.48)		
Platelet count: Week 48, n=0,2	-88888 (± 88888)	-36.0 (± 35.36)		
Platelet count: Week 52, n=1,2	30.0 (± 99999)	11.0 (± 65.05)		

Notes:

[16] - Safety Set

[17] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hematology parameter: Erythrocytes Mean Corpuscular Volume

End point title	Change from Baseline in hematology parameter: Erythrocytes Mean Corpuscular Volume
-----------------	--

End point description:

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[18]	2 ^[19]		
Units: Femtoliter (fL)				
arithmetic mean (standard deviation)				
Week 4, n=1,2	1.00 (± 99999)	-0.45 (± 0.919)		
Week 8, n=1,2	2.10 (± 99999)	-0.35 (± 0.919)		
Week 12, n=1,2	1.00 (± 99999)	2.00 (± 1.414)		
Week 16, n=1,2	3.10 (± 99999)	1.15 (± 1.344)		
Week 20, n=1,2	-0.20 (± 99999)	0.85 (± 1.202)		
Week 24, n=1,2	0.60 (± 99999)	0.95 (± 1.202)		
Week 28, n=1,2	2.60 (± 99999)	0.70 (± 1.131)		
Week 32, n=1,1	0.80 (± 99999)	1.90 (± 99999)		
Week 36, n=1,2	1.00 (± 99999)	1.25 (± 0.495)		
Week 40, n=1,2	2.10 (± 99999)	0.35 (± 1.626)		
Week 44, n=1,2	5.60 (± 99999)	0.20 (± 1.980)		
Week 48, n=0,2	-88888 (± 88888)	1.35 (± 0.778)		
Week 52, n=1,2	3.40 (± 99999)	1.45 (± 0.495)		

Notes:

[18] - Safety Set

[19] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin

End point title	Change from Baseline in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin
-----------------	--

End point description:

Blood samples were collected to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[20]	2 ^[21]		
Units: Picogram (pg)				
arithmetic mean (standard deviation)				
Week 4, n=1,2	0.30 (± 99999)	0.00 (± 0.849)		
Week 8, n=1,2	0.20 (± 99999)	0.45 (± 0.071)		
Week 12, n=1,2	0.70 (± 99999)	0.70 (± 0.141)		
Week 16, n=1,2	1.30 (± 99999)	0.95 (± 0.212)		
Week 20, n=1,2	0.90 (± 99999)	0.85 (± 0.212)		
Week 24, n=1,2	1.30 (± 99999)	0.70 (± 0.000)		
Week 28, n=1,2	1.20 (± 99999)	1.45 (± 0.212)		
Week 32, n=1,1	1.00 (± 99999)	0.40 (± 99999)		
Week 36, n=1,2	0.50 (± 99999)	1.15 (± 0.636)		
Week 40, n=1,2	1.60 (± 99999)	0.55 (± 0.212)		
Week 44, n=1,2	2.10 (± 99999)	0.55 (± 1.061)		
Week 48, n=0,2	-88888 (± 88888)	0.80 (± 0.566)		
Week 52, n=1,2	1.80 (± 99999)	1.95 (± 1.626)		

Notes:

[20] - Safety Set

[21] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)

End point title	Change from Baseline in clinical chemistry parameters: Calcium, Potassium, Sodium, Blood Urea Nitrogen (BUN)
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameters: Calcium, Potassium, Sodium and BUN. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[22]	2 ^[23]		
Units: millimoles per liter (mmol/L)				
arithmetic mean (standard deviation)				

Calcium: Week 4, n=1,2	0.0749 (± 99999)	-0.1123 (± 0.05293)		
Calcium: Week 8, n=1,2	-0.1248 (± 99999)	-0.1248 (± 0.10585)		
Calcium: Week 12, n=1,2	-0.0499 (± 99999)	-0.1372 (± 0.12350)		
Calcium: Week 16, n=1,2	0.0000 (± 99999)	-0.1372 (± 0.12350)		
Calcium: Week 20, n=1,2	0.0250 (± 99999)	-0.0873 (± 0.08821)		
Calcium: Week 24, n=1,2	0.0250 (± 99999)	-0.0873 (± 0.15878)		
Calcium: Week 28, n=1,2	-0.0499 (± 99999)	-0.1871 (± 0.08821)		
Calcium: Week 32, n=1,1	0.0250 (± 99999)	0.0000 (± 99999)		
Calcium: Week 36, n=1,2	0.1248 (± 99999)	-0.1372 (± 0.12350)		
Calcium: Week 40, n=1,2	0.0000 (± 99999)	-0.0624 (± 0.05293)		
Calcium: Week 44, n=1,2	0.1248 (± 99999)	-0.1248 (± 0.07057)		
Calcium: Week 48, n=0,2	-88888 (± 88888)	-0.1123 (± 0.08821)		
Calcium: Week 52, n=1,2	0.0998 (± 99999)	-0.1747 (± 0.14114)		
Potassium: Week 4, n=1,2	0.40 (± 99999)	-0.35 (± 0.354)		
Potassium: Week 8, n=1,2	0.30 (± 99999)	-0.40 (± 0.000)		
Potassium: Week 12, n=1,2	0.40 (± 99999)	-0.30 (± 0.283)		
Potassium: Week 16, n=1,2	0.10 (± 99999)	-0.45 (± 0.212)		
Potassium: Week 20, n=1,2	0.30 (± 99999)	-0.10 (± 0.424)		
Potassium: Week 24, n=1,2	0.20 (± 99999)	-0.05 (± 0.495)		
Potassium: Week 28, n=1,2	0.30 (± 99999)	-0.55 (± 0.354)		
Potassium: Week 32, n=1,1	0.30 (± 99999)	-0.30 (± 99999)		
Potassium: Week 36, n=1,2	0.20 (± 99999)	-0.35 (± 0.071)		
Potassium: Week 40, n=1,2	0.40 (± 99999)	-0.55 (± 0.354)		
Potassium: Week 44, n=1,2	0.20 (± 99999)	-0.40 (± 0.424)		
Potassium: Week 48, n=0,2	-88888 (± 88888)	-0.25 (± 0.495)		
Potassium: Week 52, n=1,2	0.50 (± 99999)	-0.20 (± 0.283)		
Sodium: Week 4, n=1,2	0.0 (± 99999)	0.5 (± 3.54)		
Sodium: Week 8, n=1,2	0.0 (± 99999)	-0.5 (± 0.71)		
Sodium: Week 12, n=1,2	-1.0 (± 99999)	0.0 (± 0.00)		
Sodium: Week 16, n=1,2	0.0 (± 99999)	0.5 (± 3.54)		
Sodium: Week 20, n=1,2	1.0 (± 99999)	-2.0 (± 2.83)		
Sodium: Week 24, n=1,2	0.0 (± 99999)	0.5 (± 2.12)		
Sodium: Week 28, n=1,2	-2.0 (± 99999)	-0.5 (± 3.54)		
Sodium: Week 32, n=1,1	0.0 (± 99999)	-3.0 (± 99999)		

Sodium: Week 36, n=1,2	0.0 (± 99999)	-0.5 (± 2.12)		
Sodium: Week 40, n=1,2	0.0 (± 99999)	-2.5 (± 3.54)		
Sodium: Week 44, n=1,2	1.0 (± 99999)	-0.5 (± 4.95)		
Sodium: Week 48, n=0,2	-88888 (± 88888)	-1.0 (± 2.83)		
Sodium: Week 52, n=1,2	-1.0 (± 99999)	0.5 (± 2.12)		
BUN: Week 4, n=1,2	0.9996 (± 99999)	0.0893 (± 3.40790)		
BUN: Week 8, n=1,2	-0.2142 (± 99999)	2.1242 (± 4.06424)		
BUN: Week 12, n=1,2	1.7136 (± 99999)	0.6962 (± 2.54961)		
BUN: Week 16, n=1,2	1.3923 (± 99999)	0.1964 (± 4.77106)		
BUN: Week 20, n=1,2	0.7854 (± 99999)	0.8390 (± 0.83304)		
BUN: Week 24, n=1,2	0.6069 (± 99999)	0.0000 (± 3.02925)		
BUN: Week 28, n=1,2	3.6057 (± 99999)	0.0893 (± 2.90303)		
BUN: Week 32, n=1,1	2.2134 (± 99999)	1.4280 (± 99999)		
BUN: Week 36, n=1,2	4.1055 (± 99999)	0.4820 (± 1.33792)		
BUN: Week 40, n=1,2	-0.6426 (± 99999)	4.1948 (± 7.19446)		
BUN: Week 44, n=1,2	2.2848 (± 99999)	1.1603 (± 2.90303)		
BUN: Week 48, n=0,2	-88888 (± 88888)	0.4463 (± 2.90303)		
BUN: Week 52, n=1,2	1.9278 (± 99999)	1.1424 (± 4.94777)		

Notes:

[22] - Safety Set

[23] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameter: Creatinine

End point title	Change from Baseline in clinical chemistry parameter: Creatinine
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Creatinine. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[24]	2 ^[25]		
Units: micromoles per Liter (µmol/L)				
arithmetic mean (standard deviation)				
Week 4, n=1,2	21.2160 (± 99999)	-3.0940 (± 5.62574)		
Week 8, n=1,2	139.6720 (± 99999)	-0.4420 (± 9.37624)		
Week 12, n=1,2	-1.7680 (± 99999)	3.9780 (± 10.62640)		
Week 16, n=1,2	4.4200 (± 99999)	14.5860 (± 19.37755)		
Week 20, n=1,2	-22.1000 (± 99999)	12.3760 (± 6.25082)		
Week 24, n=1,2	-5.3040 (± 99999)	24.3100 (± 26.87854)		
Week 28, n=1,2	78.6760 (± 99999)	13.7020 (± 13.12673)		
Week 32, n=1,1	83.9800 (± 99999)	48.6200 (± 99999)		
Week 36, n=1,2	95.4720 (± 99999)	32.2660 (± 45.63101)		
Week 40, n=1,2	100.7760 (± 99999)	65.4160 (± 75.00989)		
Week 44, n=1,2	115.8040 (± 99999)	49.5040 (± 57.50758)		
Week 48, n=0,2	-88888 (± 88888)	56.1340 (± 65.63365)		
Week 52, n=1,2	151.1640 (± 99999)	73.8140 (± 94.38744)		

Notes:

[24] - Safety Set

[25] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)

End point title	Change from Baseline in clinical chemistry parameters: Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) and Aspartate Aminotransferase (AST)
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameters: ALT, ALP and AST. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[26]	2 ^[27]		
Units: International units per liter				
arithmetic mean (standard deviation)				
ALT: Week 4, n=1,2	2.0 (± 99999)	-2.0 (± 0.00)		
ALT: Week 8, n=1,2	2.0 (± 99999)	-2.5 (± 0.71)		
ALT: Week 12, n=1,2	2.0 (± 99999)	-3.5 (± 0.71)		
ALT: Week 24, n=1,2	0.0 (± 99999)	-3.5 (± 2.12)		
ALT: Week 32, n=1,1	1.0 (± 99999)	-5.0 (± 99999)		
ALT: Week 36, n=1,2	-1.0 (± 99999)	-1.0 (± 0.00)		
ALT: Week 40, n=1,2	-2.0 (± 99999)	-3.5 (± 2.12)		
ALT: Week 48, n=0,2	-88888 (± 88888)	-0.5 (± 4.95)		
ALT: Week 52, n=1,2	0.0 (± 99999)	-4.5 (± 0.71)		
ALP: Week 4, n=1,1	34.0 (± 99999)	-29.0 (± 99999)		
ALP: Week 8, n=1,1	13.0 (± 99999)	77.0 (± 99999)		
ALP: Week 12, n=1,1	31.0 (± 99999)	123.0 (± 99999)		
ALP: Week 24, n=1,1	36.0 (± 99999)	23.0 (± 99999)		
ALP: Week 32, n=1,1	29.0 (± 99999)	141.0 (± 99999)		
ALP: Week 36, n=1,1	14.0 (± 99999)	113.0 (± 99999)		
ALP: Week 40, n=1,1	2.0 (± 99999)	100.0 (± 99999)		
ALP: Week 48, n=0,1	-88888 (± 88888)	35.0 (± 99999)		
ALP: Week 52, n=1,1	2.0 (± 99999)	46.0 (± 99999)		
AST: Week 4, n=1,2	3.0 (± 99999)	-1.0 (± 1.41)		
AST: Week 8, n=1,2	5.0 (± 99999)	-1.0 (± 1.41)		
AST: Week 12, n=1,2	0.0 (± 99999)	-4.0 (± 2.83)		
AST: Week 24, n=1,2	-1.0 (± 99999)	-5.5 (± 3.54)		
AST: Week 32, n=1,1	1.0 (± 99999)	-4.0 (± 99999)		
AST: Week 36, n=1,2	-2.0 (± 99999)	-2.5 (± 3.54)		
AST: Week 40, n=1,2	-3.0 (± 99999)	-4.0 (± 4.24)		
AST: Week 48, n=0,2	-88888 (± 88888)	-4.5 (± 4.95)		
AST: Week 52, n=1,2	-2.0 (± 99999)	-6.0 (± 4.24)		

Notes:

[26] - Safety Set

[27] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameters: Bilirubin and

Direct Bilirubin

End point title	Change from Baseline in clinical chemistry parameters: Bilirubin and Direct Bilirubin
-----------------	---

End point description:

Blood samples were collected to analyze the clinical chemistry parameters: Bilirubin and Direct Bilirubin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[28]	2 ^[29]		
Units: micromoles per Liter (µmol/L)				
arithmetic mean (standard deviation)				
Bilirubin: Week 4, n=1,2	0.0000 (± 99999)	1.1115 (± 1.57190)		
Bilirubin: Week 8, n=1,2	0.0000 (± 99999)	1.5390 (± 2.17647)		
Bilirubin: Week 12, n=1,2	0.0000 (± 99999)	3.4200 (± 4.83661)		
Bilirubin: Week 24, n=1,2	-1.7100 (± 99999)	4.9590 (± 2.17647)		
Bilirubin: Week 32, n=1,1	0.0000 (± 99999)	3.4200 (± 99999)		
Bilirubin: Week 36, n=1,2	0.0000 (± 99999)	1.9665 (± 0.36275)		
Bilirubin: Week 40, n=1,2	0.0000 (± 99999)	3.5910 (± 0.24183)		
Bilirubin: Week 48, n=0,2	-88888 (± 88888)	-0.3420 (± 0.48366)		
Bilirubin: Week 52, n=1,2	-1.7100 (± 99999)	1.6245 (± 2.29739)		
Direct Bilirubin: Week 4, n=1,2	0.0000 (± 99999)	0.0000 (± 0.00000)		
Direct Bilirubin: Week 8, n=1,2	0.0000 (± 99999)	0.1710 (± 0.24183)		
Direct Bilirubin: Week 12, n=1,2	0.0000 (± 99999)	0.4275 (± 0.60458)		
Direct Bilirubin: Week 24, n=1,2	0.0000 (± 99999)	0.4275 (± 0.60458)		
Direct Bilirubin: Week 32, n=1,1	0.0000 (± 99999)	0.0000 (± 99999)		
Direct Bilirubin: Week 36, n=1,2	0.0000 (± 99999)	0.0855 (± 0.12092)		
Direct Bilirubin: Week 40, n=1,2	0.0000 (± 99999)	0.0000 (± 0.00000)		
Direct Bilirubin: Week 48, n=0,2	-88888 (± 88888)	0.0855 (± 0.12092)		

Direct Bilirubin: Week 52, n=1,2	0.0000 (± 99999)	0.0855 (± 0.12092)		
----------------------------------	------------------	--------------------	--	--

Notes:

[28] - Safety Set

[29] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameter: Protein

End point title	Change from Baseline in clinical chemistry parameter: Protein
-----------------	---

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Protein. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[30]	2 ^[31]		
Units: Grams per liter				
arithmetic mean (standard deviation)				
Week 4, n=1,2	6.00 (± 99999)	-2.30 (± 1.838)		
Week 8, n=1,2	5.00 (± 99999)	-1.85 (± 1.202)		
Week 12, n=1,2	-1.00 (± 99999)	-2.65 (± 0.495)		
Week 24, n=1,2	2.00 (± 99999)	-1.45 (± 2.051)		
Week 32, n=1,1	4.00 (± 99999)	2.00 (± 99999)		
Week 36, n=1,2	6.00 (± 99999)	-1.65 (± 3.748)		
Week 40, n=1,2	3.00 (± 99999)	2.25 (± 5.303)		
Week 48, n=0,2	-88888 (± 88888)	0.10 (± 2.687)		
Week 52, n=1,2	3.00 (± 99999)	-0.65 (± 2.333)		

Notes:

[30] - Safety Set

[31] - Safety Set

Statistical analyses

Secondary: Change from Baseline in clinical chemistry parameter: Ferritin

End point title	Change from Baseline in clinical chemistry parameter: Ferritin
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Ferritin. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[32]	2 ^[33]		
Units: micrograms per liter (µg/L)				
arithmetic mean (standard deviation)				
Week 4, n=1,2	-32.00 (± 99999)	-12.60 (± 20.365)		
Week 8, n=1,2	167.00 (± 99999)	-17.30 (± 12.304)		
Week 12, n=1,2	28.00 (± 99999)	-23.30 (± 19.375)		
Week 16, n=1,2	-29.00 (± 99999)	-24.95 (± 9.970)		
Week 20, n=1,2	-35.00 (± 99999)	-28.50 (± 13.435)		
Week 24, n=1,2	-33.00 (± 99999)	-26.95 (± 22.698)		
Week 28, n=1,2	-36.00 (± 99999)	-27.65 (± 25.951)		
Week 32, n=1,1	-14.00 (± 99999)	-22.00 (± 99999)		
Week 36, n=1,2	42.00 (± 99999)	-31.00 (± 12.728)		
Week 40, n=1,2	42.00 (± 99999)	-9.60 (± 37.335)		
Week 44, n=1,2	75.00 (± 99999)	-3.00 (± 59.397)		
Week 48, n=0,2	-88888 (± 88888)	-16.30 (± 50.487)		
Week 52, n=1,2	39.00 (± 99999)	-5.05 (± 56.498)		

Notes:

[32] - Safety Set

[33] - Safety Set

Statistical analyses

Secondary: Change from Baseline in clinical chemistry parameter: Transferrin saturation

End point title	Change from Baseline in clinical chemistry parameter: Transferrin saturation
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Transferrin saturation. Transferrin saturation is measured as a percentage (%), it is the ratio of serum iron and total iron-binding capacity, multiplied by 100. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[34]	2 ^[35]		
Units: Percentage of transferrin saturation				
arithmetic mean (standard deviation)				
Week 4, n=1,2	-6.900 (± 99999)	-14.990 (± 43.8548)		
Week 8, n=1,2	-2.300 (± 99999)	6.385 (± 7.6155)		
Week 12, n=1,2	6.500 (± 99999)	-18.245 (± 68.9500)		
Week 16, n=1,2	-0.900 (± 99999)	-2.775 (± 4.5608)		
Week 20, n=1,2	-3.600 (± 99999)	-18.500 (± 55.8614)		
Week 24, n=1,2	-7.770 (± 99999)	-12.995 (± 55.1614)		
Week 28, n=1,2	-6.900 (± 99999)	-29.050 (± 56.4978)		
Week 32, n=1,1	-8.100 (± 99999)	-69.000 (± 99999)		
Week 36, n=1,2	3.100 (± 99999)	-31.620 (± 62.7628)		
Week 40, n=1,2	3.100 (± 99999)	-32.230 (± 52.0006)		
Week 44, n=1,2	-7.600 (± 99999)	-27.305 (± 27.8529)		
Week 48, n=0,2	-88888 (± 88888)	-25.715 (± 28.6873)		
Week 52, n=1,2	-1.500 (± 99999)	-7.520 (± 51.5905)		

Notes:

[34] - Safety Set

[35] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameter: Estimated Glomerular Filtration Rate

End point title	Change from Baseline in clinical chemistry parameter: Estimated Glomerular Filtration Rate
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Estimated Glomerular Filtration Rate. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[36]	2 ^[37]		
Units: milliliter per minute per 1.73 meter ²				
arithmetic mean (standard deviation)				
Week 4, n=1,2	-0.380 (± 99999)	0.615 (± 0.7990)		
Week 8, n=1,2	-2.020 (± 99999)	-0.310 (± 2.4042)		
Week 12, n=1,2	0.040 (± 99999)	-1.095 (± 3.0335)		
Week 16, n=1,2	-0.060 (± 99999)	-1.530 (± 2.0365)		
Week 20, n=1,2	0.440 (± 99999)	-1.740 (± 0.3253)		
Week 24, n=1,2	0.130 (± 99999)	-2.655 (± 2.3405)		
Week 28, n=1,2	-0.930 (± 99999)	-1.200 (± 1.2445)		
Week 32, n=1,1	-1.320 (± 99999)	-4.650 (± 99999)		
Week 36, n=1,2	-1.460 (± 99999)	-2.370 (± 5.1053)		
Week 40, n=1,2	-1.580 (± 99999)	-6.565 (± 4.3346)		

Week 44, n=1,2	-1.770 (± 99999)	-4.855 (± 4.0800)		
Week 48, n=0,2	-88888 (± 88888)	-5.410 (± 4.4548)		
Week 52, n=1,2	-2.260 (± 99999)	-5.935 (± 6.6539)		

Notes:

[36] - Safety Set

[37] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in clinical chemistry parameter: Prothrombin International Normalized Ratio

End point title	Change from Baseline in clinical chemistry parameter: Prothrombin International Normalized Ratio
-----------------	--

End point description:

Blood samples were collected to analyze the clinical chemistry parameter: Prothrombin International Normalized Ratio. It is used to assess the clotting ability of blood. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 4, 8, 12, 24, 32, 36, 40, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	1 ^[38]	1 ^[39]		
Units: Ratio				
arithmetic mean (standard deviation)				
Week 4, n=1,1	-0.010 (± 99999)	-0.010 (± 99999)		
Week 8, n=1,1	-0.040 (± 99999)	0.050 (± 99999)		
Week 12, n=1,1	0.010 (± 99999)	0.030 (± 99999)		
Week 24, n=1,1	-0.040 (± 99999)	0.010 (± 99999)		
Week 32, n=1,0	-0.010 (± 99999)	-88888 (± 88888)		
Week 36, n=1,1	0.010 (± 99999)	-0.020 (± 99999)		
Week 40, n=1,1	0.030 (± 99999)	0.010 (± 99999)		
Week 48, n=0,1	-88888 (± 88888)	-0.010 (± 99999)		

Week 52, n=1,1	0.030 (± 99999)	0.040 (± 99999)		
----------------	-----------------	-----------------	--	--

Notes:

[38] - Safety Set

[39] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP)

End point title	Change from Baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP)
-----------------	--

End point description:

Systolic and Diastolic Blood Pressure readings in millimeters of mercury (mmHg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[40]	2 ^[41]		
Units: millimeters of mercury (mmHg)				
arithmetic mean (standard deviation)				
SBP: Week 2, n=2,2	11.5 (± 9.19)	-8.0 (± 11.31)		
SBP: Week 4, n=1,2	9.0 (± 99999)	3.5 (± 7.78)		
SBP: Week 8, n=1,2	6.0 (± 99999)	-0.5 (± 16.26)		
SBP: Week 12, n=1,2	0.0 (± 99999)	-9.5 (± 7.78)		
SBP: Week 16, n=1,2	2.0 (± 99999)	-8.5 (± 2.12)		
SBP: Week 20, n=1,2	8.0 (± 99999)	-7.5 (± 9.19)		
SBP: Week 24, n=1,2	25.0 (± 99999)	-7.0 (± 2.83)		
SBP: Week 28, n=1,2	17.0 (± 99999)	0.0 (± 19.80)		
SBP: Week 32, n=1,1	20.0 (± 99999)	20.0 (± 99999)		
SBP: Week 36, n=1,2	16.0 (± 99999)	2.5 (± 14.85)		
SBP: Week 40, n=1,2	10.0 (± 99999)	-1.0 (± 28.28)		
SBP: Week 44, n=1,2	7.0 (± 99999)	-5.5 (± 0.71)		
SBP: Week 48, n=0,2	-88888 (± 88888)	4.0 (± 29.70)		
SBP: Week 52, n=1,2	4.0 (± 99999)	0.0 (± 16.97)		
DBP: Week 2, n=2,2	3.5 (± 2.12)	-7.5 (± 3.54)		
DBP: Week 4, n=1,2	19.0 (± 99999)	2.5 (± 14.85)		
DBP: Week 8, n=1,2	8.0 (± 99999)	-3.0 (± 2.83)		

DBP: Week 12, n=1,2	-4.0 (± 99999)	-1.0 (± 1.41)		
DBP: Week 16, n=1,2	5.0 (± 99999)	-8.0 (± 0.00)		
DBP: Week 20, n=1,2	4.0 (± 99999)	-10.0 (± 9.90)		
DBP: Week 24, n=1,2	16.0 (± 99999)	-4.5 (± 10.61)		
DBP: Week 28, n=1,2	6.0 (± 99999)	4.0 (± 8.49)		
DBP: Week 32, n=1,1	8.0 (± 99999)	7.0 (± 99999)		
DBP: Week 36, n=1,2	11.0 (± 99999)	5.0 (± 4.24)		
DBP: Week 40, n=1,2	2.0 (± 99999)	0.0 (± 5.66)		
DBP: Week 44, n=1,2	11.0 (± 99999)	4.5 (± 0.71)		
DBP: Week 48, n=0,2	-88888 (± 88888)	-2.0 (± 0.00)		
DBP: Week 52, n=1,2	1.0 (± 99999)	-6.0 (± 1.41)		

Notes:

[40] - Safety Set

[41] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in heart rate (HR)

End point title	Change from Baseline in heart rate (HR)
-----------------	---

End point description:

Heart rate readings in beats per minutes (bpm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[42]	2 ^[43]		
Units: beats per minute				
arithmetic mean (standard deviation)				
Week 2, n=2,2	-12.5 (± 9.19)	-9.0 (± 4.24)		
Week 4, n=1,2	2.0 (± 99999)	-2.0 (± 18.38)		
Week 8, n=1,2	15.0 (± 99999)	-8.0 (± 28.28)		
Week 12, n=1,2	5.0 (± 99999)	-11.0 (± 43.84)		
Week 16, n=1,2	-10.0 (± 99999)	-12.0 (± 14.14)		
Week 20, n=1,2	0.0 (± 99999)	4.0 (± 14.14)		
Week 24, n=1,2	8.0 (± 99999)	5.5 (± 6.36)		
Week 28, n=1,2	14.0 (± 99999)	3.0 (± 5.66)		

Week 32, n=1,1	11.0 (± 99999)	-12.0 (± 99999)		
Week 36, n=1,2	1.00 (± 99999)	3.5 (± 7.78)		
Week 40, n=1,1	-1.0 (± 99999)	30.0 (± 99999)		
Week 44, n=1,2	12.0 (± 99999)	-3.5 (± 12.02)		
Week 48, n=0,2	-88888 (± 88888)	-17.5 (± 14.85)		
Week 52, n=1,2	-3.0 (± 99999)	3.0 (± 1.41)		

Notes:

[42] - Safety Set

[43] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in weight

End point title	Change from Baseline in weight
-----------------	--------------------------------

End point description:

Weight readings in kilogram (kg) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[44]	2 ^[45]		
Units: kilograms (Kg)				
arithmetic mean (standard deviation)				
Week 2, n=2,2	-1.00 (± 0.141)	-0.70 (± 0.566)		
Week 4, n=1,2	-1.80 (± 99999)	-0.25 (± 1.485)		
Week 8, n=1,2	-2.40 (± 99999)	0.40 (± 0.141)		
Week 12, n=1,2	1.20 (± 99999)	1.00 (± 0.566)		
Week 16, n=1,2	-0.50 (± 99999)	0.60 (± 0.283)		
Week 20, n=1,2	2.20 (± 99999)	0.70 (± 0.849)		
Week 24, n=1,2	2.00 (± 99999)	0.45 (± 0.212)		
Week 28, n=1,2	1.70 (± 99999)	0.80 (± 0.990)		
Week 32, n=1,1	1.00 (± 99999)	1.90 (± 99999)		
Week 36, n=1,2	0.20 (± 99999)	0.95 (± 1.768)		
Week 40, n=1,2	0.80 (± 99999)	0.95 (± 1.061)		
Week 44, n=1,2	1.50 (± 99999)	1.85 (± 0.495)		

Week 48, n=0,2	-88888 (± 88888)	2.90 (± 0.000)		
Week 52, n=1,2	1.30 (± 99999)	2.70 (± 0.000)		

Notes:

[44] - Safety Set

[45] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in height

End point title	Change from Baseline in height
-----------------	--------------------------------

End point description:

Height readings in centimeters (cm) were collected. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[46]	2 ^[47]		
Units: centimeters (cm)				
arithmetic mean (standard deviation)				
Week 2, n=2,2	-1.50 (± 2.121)	0.85 (± 1.202)		
Week 4, n=1,2	0.00 (± 99999)	0.95 (± 0.495)		
Week 8, n=1,2	0.00 (± 99999)	1.20 (± 0.707)		
Week 12, n=1,2	0.00 (± 99999)	2.65 (± 0.071)		
Week 16, n=1,2	0.10 (± 99999)	1.85 (± 1.485)		
Week 20, n=1,2	0.30 (± 99999)	3.35 (± 0.495)		
Week 24, n=1,2	0.30 (± 99999)	3.70 (± 0.707)		
Week 28, n=1,2	1.00 (± 99999)	4.60 (± 0.141)		
Week 32, n=1,1	0.80 (± 99999)	5.30 (± 99999)		
Week 36, n=1,2	0.50 (± 99999)	5.00 (± 1.131)		
Week 40, n=1,2	0.20 (± 99999)	4.50 (± 2.546)		
Week 44, n=1,2	0.20 (± 99999)	5.65 (± 2.192)		
Week 48, n=0,2	-88888 (± 88888)	5.65 (± 2.192)		
Week 52, n=1,2	-0.70 (± 99999)	6.25 (± 2.333)		

Notes:

[46] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Absolute values of hemoglobin (Hgb)

End point title	Absolute values of hemoglobin (Hgb)
-----------------	-------------------------------------

End point description:

Blood samples were collected from all participants for measurement of Hgb values in grams per deciliter (g/dL). Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Hgb results of a single participant of both the arms from Week 8 to Week 52 (for participants requiring Dialysis) and from Week 40 to Week 52 (for participants not requiring Dialysis) were excluded from summary due to intercurrent events. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[48]	2 ^[49]		
Units: grams per deciliter				
arithmetic mean (standard deviation)				
Baseline (Day 1), n=2,2	11.00 (± 0.424)	11.35 (± 0.919)		
Week 2, n=2,2	10.85 (± 1.061)	11.90 (± 0.990)		
Week 4, n=1,2	11.80 (± 99999)	11.50 (± 0.566)		
Week 8, n=0,2	-88888 (± 88888)	11.65 (± 0.212)		
Week 12, n=0,2	-88888 (± 88888)	11.80 (± 0.283)		
Week 16, n=0,2	-88888 (± 88888)	10.95 (± 0.495)		
Week 20, n=0,2	-88888 (± 88888)	11.55 (± 0.212)		
Week 24, n=0,2	-88888 (± 88888)	11.70 (± 0.141)		
Week 28, n=0,2	-88888 (± 88888)	11.65 (± 0.354)		
Week 32, n=0,1	-88888 (± 88888)	11.80 (± 99999)		
Week 36, n=0,2	-88888 (± 88888)	11.95 (± 0.354)		

Week 40, n=0,1	-88888 (± 88888)	12.10 (± 99999)		
Week 44, n=0,1	-88888 (± 88888)	11.20 (± 99999)		
Week 48, n=0,1	-88888 (± 88888)	11.90 (± 99999)		
Week 52, n=0,1	-88888 (± 88888)	12.60 (± 99999)		

Notes:

[48] - Safety Set

[49] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change from Baseline in hemoglobin (Hgb)

End point title	Change from Baseline in hemoglobin (Hgb)
End point description:	
Blood samples were collected from all participants for measurement of Hgb values in g/dL. Baseline value was defined as the last non-missing value prior to the start date and time of the study medication (Day 1). Change from Baseline was calculated as the value at indicated time point minus the value at Baseline. Hgb results of a single participant of both the arms from Week 8 to Week 52 (for participants requiring Dialysis) and from Week 40 to Week 52 (for participants not requiring Dialysis) were excluded from summary due to intercurrent events. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.	
End point type	Secondary
End point timeframe:	
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[50]	2 ^[51]		
Units: grams per Liter				
arithmetic mean (standard deviation)				
Week 2, n=2,2	-0.15 (± 0.636)	0.55 (± 0.071)		
Week 4, n=1,2	0.5 (± 99999)	0.15 (± 1.485)		
Week 8, n=0,2	-88888 (± 88888)	0.30 (± 1.131)		
Week 12, n=0,2	-88888 (± 88888)	0.45 (± 0.636)		
Week 16, n=0,2	-88888 (± 88888)	-0.40 (± 1.414)		
Week 20, n=0,2	-88888 (± 88888)	0.20 (± 0.707)		
Week 24, n=0,2	-88888 (± 88888)	0.35 (± 1.061)		
Week 28, n=0,2	-88888 (± 88888)	0.30 (± 1.273)		

Week 32, n=0,1	-88888 (± 88888)	1.10 (± 99999)		
Week 36, n=0,2	-88888 (± 88888)	0.60 (± 0.566)		
Week 40, n=0,1	-88888 (± 88888)	0.10 (± 99999)		
Week 44, n=0,1	-88888 (± 88888)	-0.80 (± 99999)		
Week 48, n=0,1	-88888 (± 88888)	-0.10 (± 99999)		
Week 52, n=0,1	-88888 (± 88888)	0.60 (± 99999)		

Notes:

[50] - Safety Set

[51] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with Hgb values above, below and within the target range (10 to 12 g/dL)

End point title	Number of participants with Hgb values above, below and within the target range (10 to 12 g/dL)
End point description:	
Number of participants with Hgb values above, below, and within the target range (10 to 12 g/dL) were assessed. Baseline assessment was defined as the last non-missing value prior to the start date and time of the study drug (Day 1). Hgb results of a single participant of both the arms from Week 8 to Week 52 (for participants requiring Dialysis) and from Week 40 to Week 52 (for participants not requiring Dialysis) were excluded from summary due to intercurrent events. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles).	
End point type	Secondary
End point timeframe:	
Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48 and 52	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[52]	2 ^[53]		
Units: Participants				
Baseline (Day 1): Above Target Range, n=2,2	0	0		
Week 2: Above Target Range, n=2,2	0	1		
Week 4: Above Target Range, n=1,2	0	0		
Week 8: Above Target Range, n=0,2	0	0		
Week 12: Above Target Range, n=0,2	0	0		
Week 16: Above Target Range, n=0,2	0	0		
Week 20: Above Target Range, n=0,2	0	0		
Week 24: Above Target Range, n=0,2	0	0		
Week 28: Above Target Range, n=0,2	0	0		
Week 32: Above Target Range, n=0,1	0	0		

Week 36: Above Target Range, n=0,2	0	1		
Week 40: Above Target Range, n=0,1	0	1		
Week 44: Above Target Range, n=0,1	0	0		
Week 48: Above Target Range, n=0,1	0	0		
Week 52: Above Target Range, n=0,1	0	1		
Baseline (Day 1): Within Target Range, n=2,2	2	2		
Week 2: Within Target Range, n=2,2	2	1		
Week 4: Within Target Range, n=1,2	1	2		
Week 8: Within Target Range, n=0,2	0	2		
Week 12: Within Target Range, n=0,2	0	2		
Week 16: Within Target Range, n=0,2	0	2		
Week 20: Within Target Range, n=0,2	0	2		
Week 24: Within Target Range, n=0,2	0	2		
Week 28: Within Target Range, n=0,2	0	2		
Week 32: Within Target Range, n=0,1	0	1		
Week 36: Within Target Range, n=0,2	0	1		
Week 40: Within Target Range, n=0,1	0	0		
Week 44: Within Target Range, n=0,1	0	1		
Week 48: Within Target Range, n=0,1	0	1		
Week 52: Within Target Range, n=0,1	0	0		
Baseline (Day 1): Below Target Range, n=2,2	0	0		
Week 2: Below Target Range, n=2,2	0	0		
Week 4: Below Target Range, n=1,2	0	0		
Week 8: Below Target Range, n=0,2	0	0		
Week 12: Below Target Range, n=0,2	0	0		
Week 16: Below Target Range, n=0,2	0	0		
Week 20: Below Target Range, n=0,2	0	0		
Week 24: Below Target Range, n=0,2	0	0		
Week 28: Below Target Range, n=0,2	0	0		
Week 32: Below Target Range, n=0,1	0	0		
Week 36: Below Target Range, n=0,2	0	0		
Week 40: Below Target Range, n=0,1	0	0		
Week 44: Below Target Range, n=0,1	0	0		
Week 48: Below Target Range, n=0,1	0	0		
Week 52: Below Target Range, n=0,1	0	0		

Notes:

[52] - Safety Set

[53] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Change in Daprodustat dose from starting dose at each study time point

End point title	Change in Daprodustat dose from starting dose at each study time point
-----------------	--

End point description:

Daprodustat dose was adjusted during the study based on participant's Hgb levels. Dose change values of daprodustat from starting dose at each study time point were calculated as dose level at indicated time point minus starting dose at Day 1. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time

points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant. 88888 indicates data is not available.

End point type	Secondary
End point timeframe:	
Day 1, at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[54]	2 ^[55]		
Units: milligrams				
arithmetic mean (standard deviation)				
Week 2, n=2,2	0 (± 0)	-1 (± 1.41)		
Week 4, n=1,2	0 (± 99999)	-0.5 (± 0.71)		
Week 8, n=1,2	-6 (± 99999)	-0.5 (± 0.71)		
Week 12, n=1,2	-2 (± 99999)	-0.5 (± 0.71)		
Week 16, n=1,2	0 (± 99999)	-0.5 (± 0.71)		
Week 20, n=1,2	0 (± 99999)	-0.5 (± 0.71)		
Week 24, n=1,2	0 (± 99999)	-0.5 (± 0.71)		
Week 28, n=1,2	-2 (± 99999)	-0.5 (± 0.71)		
Week 32, n=1,1	-6 (± 99999)	0 (± 99999)		
Week 36, n=1,2	-4 (± 99999)	-1 (± 1.41)		
Week 40, n=1,2	-4 (± 99999)	-2 (± 0)		
Week 44, n=1,2	-4 (± 99999)	-1 (± 0)		
Week 48, n=0,2	-88888 (± 88888)	-1 (± 99999)		

Notes:

[54] - Safety Set

[55] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Number of participants with 0 to 10, or greater than (>) 10 dose adjustments

End point title	Number of participants with 0 to 10, or greater than (>) 10 dose adjustments
End point description:	
Number of participants who required dapurodistat dose adjustments from the starting dose were assessed. Data was categorized for number of participants who required no dose change (0 times) to 10 times and >10times dose adjustments during the study. Safety Set.	
End point type	Secondary
End point timeframe:	
Up to Week 52	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[56]	2 ^[57]		
Units: Participants				
No dose change (0 time)	1	0		
1 time	0	0		
2 times	0	1		
3 times	0	0		
4 times	0	0		
5 times	0	0		
6 times	1	1		
7 times	0	0		
8 times	0	0		
9 times	0	0		
10 times	0	0		
>10 times	0	0		

Notes:

[56] - Safety Set

[57] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Daprodustat Dose at each study time point

End point title	Daprodustat Dose at each study time point
-----------------	---

End point description:

Mean and standard deviation of Daprodustat Dose received by participants at each study time point has been presented. Safety Set. Only those participants who were measured and analyzed (i.e., contributed data reported in the table) were included in the Overall Number of Participants Analyzed field. 'Number Analyzed' signifies participants evaluable for the specified time points (represented by n=X in category titles). 99999 indicates that standard deviation could not be calculated for single participant.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline (Day 1), at Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 and 48

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[58]	2 ^[59]		
Units: milligrams				
arithmetic mean (standard deviation)				
Baseline (Day 1), n=2,2	6.0 (± 0.0000)	2.0 (± 0.00)		
Week 2, n=2,2	6.0 (± 0.0000)	1.0 (± 1.41)		
Week 4, n=1,2	6.0 (± 99999)	1.5 (± 0.71)		
Week 8, n=1,2	0.0 (± 99999)	1.5 (± 0.71)		
Week 12, n=1,2	4.0 (± 99999)	1.5 (± 0.71)		
Week 16, n=1,2	6.0 (± 99999)	1.5 (± 0.71)		

Week 20, n=1,2	6.0 (± 99999)	1.5 (± 0.71)		
Week 24, n=1,2	6.00 (± 99999)	1.5 (± 0.71)		
Week 28, n=1,2	4.0 (± 99999)	1.5 (± 0.71)		
Week 32, n=1,1	0.0 (± 99999)	2.0 (± 99999)		
Week 36, n=1,2	2.0 (± 99999)	1.0 (± 1.41)		
Week 40, n=1,2	2.0 (± 99999)	0.0 (± 0.00)		
Week 44, n=1,2	2.0 (± 99999)	1.0 (± 0.00)		
Week 48, n=0,1	-88888 (± 88888)	1.0 (± 99999)		

Notes:

[58] - Safety Set

[59] - Safety Set

Statistical analyses

No statistical analyses for this end point

Secondary: Maximum plasma concentration (Cmax) of daprodustat

End point title	Maximum plasma concentration (Cmax) of daprodustat
-----------------	--

End point description:

Blood samples were collected for the plasma concentrations of daprodustat from which pharmacokinetic (PK) parameters were determined. Mean and standard deviation of daprodustat Cmax at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis). The analysis was performed on the All Pharmacokinetic Set that included all participants in the Safety analysis who had at least 1 non-missing PK assessment (non-quantifiable values will be considered as non-missing values).

End point type	Secondary
----------------	-----------

End point timeframe:

Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[60]	2 ^[61]		
Units: Nanograms per milliliters (ng/mL)				
arithmetic mean (standard deviation)	115.047 (± 3.854)	19.447 (± 10.770)		

Notes:

[60] - All Pharmacokinetic Set

[61] - All Pharmacokinetic Set

Statistical analyses

No statistical analyses for this end point

Secondary: Area under the curve (AUC) at steady state of daprodustat

End point title	Area under the curve (AUC) at steady state of daprodustat
-----------------	---

End point description:

Blood samples were collected for the plasma concentrations of daprodustat from which PK parameters were determined. Mean and standard deviation of daprodustat AUC at steady state obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis). All Pharmacokinetic Set.

End point type	Secondary
End point timeframe:	
Day 1: 1, 2 and 6 hours Post-dose; Week 2: Pre-dose and 1, 2 and 6 hours Post-dose	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[62]	2 ^[63]		
Units: Hours*nanogram per milliliter (h*ng/mL)				
arithmetic mean (standard deviation)	185.379 (± 8.661)	56.634 (± 6.009)		

Notes:

[62] - All Pharmacokinetic Set

[63] - All Pharmacokinetic Set

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma concentrations of daprodustat and metabolites at pre-dose (Ctrough)

End point title	Plasma concentrations of daprodustat and metabolites at pre-dose (Ctrough)
-----------------	--

End point description:

Blood samples were collected for the plasma concentrations of daprodustat and metabolites from which PK parameters were determined. Mean and standard deviation of raw daprodustat and metabolites (GSK2391220, GSK2487818, GSK2506102, GSK2506104, GSK2531398 and GSK2531401) at steady state at pre-dose obtained via modeling in each sub-trial (requiring Dialysis and not yet requiring Dialysis). All Pharmacokinetic Set. 99999 indicates that data could not be calculated as the concentration values were below the lower limit of quantification. 88888 indicates standard deviation could not be calculated as a single participant was analyzed.

End point type	Secondary
End point timeframe:	
Pre-dose on Week 2	

End point values	Participants requiring Dialysis (D)	Participants not yet requiring Dialysis (ND)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	2 ^[64]	2 ^[65]		
Units: Nanograms per milliliters (ng/mL)				
arithmetic mean (standard deviation)				
Daprodustat	0.4995 (± 0.3698)	99999 (± 99999)		
GSK2391220	6.540 (± 2.206)	99999 (± 99999)		
GSK2487818	0.869 (± 0.137)	99999 (± 99999)		
GSK2506102	3.040 (± 0.424)	99999 (± 99999)		

GSK2506104	10.55 ($\pm$ 3.18)	0.143 ($\pm$ 88888)		
GSK2531398	2.490 ($\pm$ 0.184)	99999 ($\pm$ 99999)		
GSK2531401	11.25 ($\pm$ 1.48)	0.127 ($\pm$ 88888)		

Notes:

[64] - All Pharmacokinetic Set

[65] - All Pharmacokinetic Set

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

All-cause mortality, serious adverse events (SAEs) and non-serious adverse events (Non-SAEs) were collected up to 56 weeks.

Adverse event reporting additional description:

All-cause mortality, SAEs and non-SAEs were reported for Safety Set which included participants who were enrolled and received at least one dose of study medication.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	27.1
--------------------	------

Reporting groups

Reporting group title	Participants not yet requiring Dialysis (ND)
-----------------------	--

Reporting group description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the non-dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Reporting group title	Participants requiring Dialysis (D)
-----------------------	-------------------------------------

Reporting group description:

Participants received daprodustat orally once daily (QD) from Day 1 up to 52 weeks in the dialysis sub-trial. The dose of daprodustat was adjusted, if required, one step at a time in the range of 1 to 24 mg, to maintain the target range for hemoglobin (Hgb) between 10 to 12 grams per deciliter (g/dL).

Serious adverse events	Participants not yet requiring Dialysis (ND)	Participants requiring Dialysis (D)	
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events			
Congenital, familial and genetic disorders			
Congenital uterine anomaly			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			

Retroperitoneal haematoma			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 0 %

Non-serious adverse events	Participants not yet requiring Dialysis (ND)	Participants requiring Dialysis (D)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	2 / 2 (100.00%)	2 / 2 (100.00%)	
Investigations			
Serum ferritin increased			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Injury, poisoning and procedural complications			
Foot fracture			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 2 (0.00%)	1 / 2 (50.00%)	
occurrences (all)	0	1	
Infections and infestations			
Nasopharyngitis			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	2	0	
COVID-19			
subjects affected / exposed	1 / 2 (50.00%)	0 / 2 (0.00%)	
occurrences (all)	1	0	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 June 2022	Amendment 01: The primary rationale for Amendment 01 is to add the requirement for a temporary dose hold if the hemoglobin (Hgb) at Week 2 is greater than 12.5 g/dL. Additional changes are to provide further clarity of study requirements and to address regulatory feedback.
18 November 2022	Amendment 02: The primary rationale for Amendment 02 is to include heart failure (HF) and esophageal/gastric erosions as adverse events of special interest (AESIs) following recent review of the clinical trial data in the adult daprodustat global development program.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? Yes

Date	Interruption	Restart date
16 May 2024	Pause in recruitment. Recruitment was never restarted.	-

Notes:

Limitations and caveats

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As the study was terminated early, only one age group 12 to <18 years of age was recruited as per the study design. As a result of low enrollment in study, no meaningful conclusions with respect to primary and secondary objectives could be reached.

Notes: